

PATENTS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Marlon D. Cowart, et al.

Serial No.: (not yet assigned)  
(*Divisional of 10/094,265 filed on March 8, 2002*)

Filed: October 31, 2003

Title: BENZIMIDAZOLES THAT ARE  
USEFUL IN TREATING SEXUAL  
DYSFUNCTION

Case No.: 6789.US.D1

Examiner: (not yet assigned)

Group Art Unit: (not yet assigned)


EXPRESS MAIL NO.: EV314253307US

**Certificate of Mailing under 37 CFR §1.10:**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail Post Office to Addressee Service with sufficient postage in an envelope addressed as follows:

MS Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Date of Deposit: 10/31/03

  
Miriam Smith

**INFORMATION DISCLOSURE STATEMENT**

MS Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Dear Sir:

The following information is submitted, pursuant to 37 CFR §§1.97-1.98 in accordance with Applicant's duty of disclosure under 37 CFR §1.56. This submission is not intended to constitute an admission that any patent, publication or other information cited herein is "prior art" as to the invention claimed. In accordance with 37 CFR §§1.97(g)-(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that other material information as defined by 37 CFR §1.56(a) exists.

Applicants submit herewith Forms PTO 1449 listing the references known to them. Applicants respectfully request that the Examiner (1) initial each reference listed on the enclosed Forms PTO 1449 indicating that the Examiner has considered and made those references of record in this application and (2) return a copy of the initialed Forms PTO 1449 to Applicants. Copies of references were previously submitted in U.S. Serial No. 10/094,265, filed March 8, 2002, from which this application claims priority.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits under 37 CFR §1.97(b). Accordingly, no charge is required.

Respectfully submitted,  
Marlon D. Cowart, et al.

  
Michael J. Ward  
Registration No. 37,960  
Attorney for Applicants

ABBOTT LABORATORIES  
Customer No.: 23492  
Telephone: (847) 938-3490  
Facsimile: (847) 938-2623

DATE: October 31, 2003

SHEET 1 of 4

## Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. <b>6789.US.D1</b>	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT(S) <b>M. D. Cowart, et al.</b>	
(Use several sheets if necessary)		FILING DATE <b>October 31, 2003</b>	GROUP
(37 CFR 1.98 (b))			

## U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	5,714,854	02/03/98	Mizuta et al.			
	A2	5,792,768	08/11/98	Kulagowski et al.			
	A3	3,472,854	10/14/69				

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
							YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Andersson, K. et al., "Physiology of penile erection," <i>Physiol. Rev.</i> 75:191-236 (1995)
C2	Bendele, A.M. et al., "Anti-Inflammatory Activity of Pergolide, a Dopamine Receptor Agonist," <i>Journal of Pharmacology and Experimental Therapeutics</i> 259(1):169-175 (1991)
C3	Berge, S.M. et al., <i>J. Pharmaceutical Sciences</i> 66:1et seq (1977)
C4	Chen, F.F. et al., "Effects of dopamine, Apomorphine, -Hydroxybutyric Acid, Haloperidol and Pimozide on Reflex Bradycardia in Rats," <i>Journal of Pharmacology and Experimental Therapeutics</i> 214(2):427-432 (1980)
C5	DeGroat, W. et al., "Neural Control of Penile Erection, in : <i>Nervous control of urogenital system</i> ," <i>Hardwood Academic Publishers, Chur, Switzerland</i> , Vol. 3 (ed. Maggi, C.):467-524 (1993)
C6	Dula, E. et al., "Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction," <i>Urology</i> 56:130-135 (2000)
C7	Hahn, R.A. et al., "Primate Cardiovascular Responses Mediated by Dopamine Receptors: Effects of N, N-di-n-Propyldopamine and LY171555," <i>Journal of Pharmacology and Experimental therapeutics</i> 229(1):132-138 (1984)
C8	Harris, M. C. et al., "Sequential N-Arylation of Primary Amines as a Route to Alkyldiarylamines," <i>J. Org. Chem.</i> 64:6019-6022 (1999)
C9	Hrib, N. J., et al., "The dopamine D <sub>4</sub> receptor: a controversial therapeutic target," <i>Drugs of the Future</i> 2000 25(6):587-611
C10	Koch, V. et al., "Chemistry of 3-Hydroxypyridien part 2: Synthesis of 5,6-Dihalo-3hydroxypyridines," <i>Synthesis</i> 499-501 (1990)
C11	Lissoni, et al., "Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia," <i>Neuroendocrinology Letters</i> ISSN 21:405-408 (2000)
C12	Lynch, J.K. et al., "Efficient asymmetric synthesis of ABT-594; a potent, orally effective analgesic," <i>Tetrahedron: Asymmetry</i> 9:2791-2794 (1998)
C13	Melis, M et al., "Dopamine and Sexual Behavior," <i>Neuroscience and Biobehavioral Reviews</i> , 19(1):193-35 (1995)

DATE: October 31, 2003 SHEET 4 of 4

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. <b>6789.US.D1</b>	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		APPLICANT(S) <b>M.D. Cowart, et al.</b>	
		FILING DATE <b>October 31, 2003</b>	GROUP
(37 CFR 1.98 (b))			

**U.S.PATENT DOCUMENTS**

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
		3,362,956	01/09/68				
		5,714,498	02/03/98	Kulagowski et al			

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS-LATION YES NO
		02/88093	07.11.02	WO			

**OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)**

	Shvedov et al., "Catalytic alkylation of amines with alcohols," Zhurnal Organicheskoi Khimii 6(9):1838-1840 (1970)
	Pugsley et al., "The discovery of PD89211 and related compounds: selective dopamine D4 receptor antagonists," Progress in Neuro-Psychopharmacology & Biological Psychiatry 26(2):219-226 (2002)

**EXAMINER** **DATE CONSIDERED**

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

DATE: October 31, 2003

SHEET 2 of 4

## Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. <b>6789.US.D1</b>	SERIAL NO. <b>(not yet assigned)</b>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		APPLICANT(S) <b>M. D. Cowart, et al.</b>	
		FILING DATE <b>October 31, 2003</b>	GROUP <b>(not yet assigned)</b>
(37 CFR 1.98 (b))			

C14	Milligan, G. et al., "Chimaeric G proteins: their potential use in drug discovery," Trends Pharmacol Sci 20:118-124 (1998)
C15	Missale, C. et al. "Dopamine receptors: from structure to function," Physiol Rev 78:189-225 (1998)
C16	Morales, A. et al., "Oral and Topical Treatment of Erectile Dysfunction: present and future," Urologic Clinics of North America, vol. 22:879-886 (1995)
C17	Moreland, RB, et al., "Prospectives for Pharmacotherapy of Male Erectile Dysfunction," Curr Opinion CPNS Invest Drugs, 2:283-302 (2000)
C18	Padma-Nathan, H. et al., "Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction," Urology 161:214 (abstract '821) (1999)
C19	Primus, R. et al., "Localization and characterization of dopamine D <sub>4</sub> binding sites in rat and human brain by use of the novel D <sub>4</sub> receptor-selective ligand [ <sup>3</sup> H]NGD 94-1," J. Pharmacol Exp. Ther 282:1020-1027 (1997)
C20	Sule, D.P. et al., "Synthesis and Anthelmintic activity of 2-(N4-Substituted-N1-Piperazinyl) Methyl 5-(or 6)-substituted benzimidazoles," Bull. Haffkine Inst. 6(2):62-64 (1978)
C21	Suzuki, M. et al., "D <sub>3</sub> dopamine receptor mRNA is widely express in human brain," Brian Res 779:58-74 (1998)
C22	Vallone, D. et al., "Structure and function of dopamine receptors," Neurosci Biobehav. Rev. 24:125-132 (2000)
C23	Wagaw, S. et al., "The Synthesis of Aminopyridines: A Method Employing Palladium-Catalyzed Carbon-Nitrogen Bond Formation," J. Org. Chem 61:7240-7241 (1996)
C24	Yang B. et al., "Palladium-catalyzed amination of aryl halides and sulfonates," Journal of Organometallic Chemistry 576:125-146 (1999)
C25	"IUPAC 1974 Recommendation for Section E, Fundamental Stereochemistry," Pure Appl. Chem. 45:13-30 (1976)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

DATE: October 31, 2003 SHEET 3 of 4

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. <b>6789.US.D1</b>	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		APPLICANT(S) <b>M.D. Cowart, et al.</b>	
		FILING DATE <b>October 31, 2003</b>	GROUP
(37 CFR 1.98 (b))			

**U.S.PATENT DOCUMENTS**

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
		98/31368	23.07.98	WO			
		00/23056	27.04.00	WO			
		0 882 718	09.12.98	EP			
		0 468 884	24.07.91	EP			X
		2 154 605	14.09.99	ES			X

**OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)**

	Bivalacqua et al., "Pharmacotherapy for erectile dysfunction," TIPS 21:484-489 (2000)

EXAMINER	DATE CONSIDERED

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)